RecruitingPhase 2NCT05463848

Surgical Pembro +/- Olaparib w TMZ for rGBM

A Surgical "Window-of-Opportunity" and Phase II Trial of Pembrolizumab, Olaparib and Temozolomide in Recurrent Glioblastoma

Sponsor

L. Nicolas Gonzalez Castro, MD, PhD

Enrollment

78 participants

Start Date

Oct 21, 2022

Study Type

INTERVENTIONAL

Conditions

Glioblastoma Recurrent Glioblastoma

Summary

This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment. The names of the study interventions involved in this study are/is: * Pembrolizumab * Olaparib * Temozolomide (Temodar)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a combination of three drugs — pembrolizumab (immunotherapy), olaparib (a DNA-repair inhibitor), and temozolomide (chemotherapy) — for people with recurrent glioblastoma (the most aggressive form of brain cancer) after surgical removal of the tumor. Researchers want to see if this combination can extend survival. **You may be eligible if...** - You are 18 or older with recurrent glioblastoma (WHO Grade IV IDH wildtype) - You have already received surgery, radiation, and temozolomide for your brain cancer - Your tumor is visible on MRI and can be surgically removed again - Your overall health is adequate (ECOG performance status 0–2) **You may NOT be eligible if...** - You have had prior immunotherapy for glioblastoma - You have had more than 2 prior recurrences - You have active autoimmune disease or are on immunosuppressive therapy - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.